For example, we recently developed an EZH2 PROTAC degrader, which effectively targeted both canonical and noncanonical functions of EZH2, resulting in far superior tumor suppressive effects compared to catalytic inhibitors of EZH2.[24]. The gene discussed is EZH2; the disease is neoplasm.